- Sunshine Biopharma Inc SBFM has entered into a collaboration agreement with a North American lipid nanoparticle (LNP) company to advance the development of its mRNA-based anticancer macromolecule, K1.1.
- The company's collaboration partner will prepare two LNP formulations (K1.1a and K1.1b) of Sunshine Biopharma's in-house developed antineoplastic mRNA, K1.1.
- Sunshine Biopharma previously showed that its K1.1 mRNA could destroy cancer cells in vitro, including multidrug-resistant breast, ovarian adenocarcinoma, and pancreatic cancer cells.
- Also Read: EXCLUSIVE: Sunshine Biopharma Acquires Canadian Generic Player For $22M
- Parallel studies using normal human cells showed that K1.1 mRNA had little or no cytotoxic effects.
- The partner-generated K1.1a::LNP and K1.1b::LNP will be used to conduct in vivo studies on xenograft mice expressing the in vitro tested human cancers and liver cancer.
- The company can rapidly advance to conducting human trials if these mice studies prove successful. The LNP-formulated K1.1 mRNA can be readily adapted for delivery into patients using the mRNA vaccine technology.
- Price Action: SBFM shares are down 0.23% at $0.84 on the last check Wednesday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.